Pro-Pharmaceuticals, Inc. (OTC: PRWP), the leading developer of therapeutics that target Galectin proteins to treat cancer and fibrosis, today announced that the Japan Patent Office has accepted a new patent, No. 2002-574987, "Co-administration of a Polysaccharide with a Chemotherapy for the Treatment of Cancer". The patent protects, among other things, methods for reducing the toxicity of chemotherapies in which a polysaccharide, such as the Company's lead drug DAVANAT^®, is co-administered with a chemotherapeutic agent to reduce toxicity of the chemotherapy. This is the seventh patent in Pro-Pharmaceuticals growing patent portfolio that covers its core Galectin-targeting compounds and further reinforces the proprietary nature of DAVANAT^®, the Company's lead drug, in major markets around the world.

“Co-administration of a Polysaccharide with a Chemotherapy for the Treatment of Cancer”

In 2010, the Japanese pharmaceutical market was the second largest in the world, with a value of $58.5 billion, according to Visiongain, an independent business information provider.

"We continue to strengthen our intellectual property portfolio beyond the U.S. We expect similar success with additional patent applications pending in Europe, Brazil, and other key markets," said Peter G. Traber, M.D., President and CEO, Pro-Pharmaceuticals. "The new patent covers the administration of a therapeutic agent to cancer patients to enhance efficacy while substantially reducing toxicity and the well-known, undesirable side effects suffered by most chemotherapy patients. The patent also allows claims for the composition of matter for DAVANAT^® itself.

"Our technology improves the efficacy and safety profile of chemotherapy by targeting Galectins, which are proteins involved in the progression of cancer. Based on data in our own studies as well as third party studies at major international laboratories, we are confident that our Galectin-targeting compounds will soon play a major role in advancing the treatment of cancer and liver fibrosis," said Anatole Klyosov, Ph.D., D.Sc., Chief Scientist, Pro-Pharmaceuticals.

SOURCE Pro-Pharmaceuticals, Inc.

专业制药公司（OTC：PRWP）的领先开发商和纤维化的药物治疗这一目标半乳糖凝集素蛋白来治疗癌症，今天宣布，日本专利局已接受了新的专利号2002-574987，“共同管理对一个充满了治疗癌症的化疗“多糖。该专利保护，除其他外，化疗方法对降低化疗毒性的铅，其中的多糖，如本公司药物DAVANAT ^®，同为共同管理的一剂，以减少化疗毒性。这是制药专业成长第七专利的专利组合，涵盖其核心半乳糖凝集素靶向化合物，并进一步强化了所有权性质DAVANAT ^®，公司的主要毒品的世界，周围的主要市场。

“共同管理的多糖具有治疗癌症的化疗”

2010年，日本药品市场是世界上第二大，拥有五百八十五万点零万美元值，根据Visiongain，一个独立的商业信息供应商。

“我们将继续加强我们在美国以外的知识产权组合，我们期待与更多的专利，在欧洲，巴西和其他主要市场正在申请类似的成功，”彼得说克特拉伯，医学博士，总裁兼首席执行官，有利于药品。 “新的专利代理管理涵盖了癌症患者的治疗，以提高疗效，同时大大减少毒性和众所周知的，不良的副作用患者遭受化疗效果最。这项专利还允许DAVANAT物质的组成为自己索赔